Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00LSI
|
|||
| Former ID |
DCL001252
|
|||
| Drug Name |
Vidofludimus
|
|||
| Synonyms |
Vidofludimus; 717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K52.3] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | ||
| Company |
4SC AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H18FNO4
|
|||
| Canonical SMILES |
COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
|
|||
| InChI |
1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
|
|||
| InChIKey |
XPRDUGXOWVXZLL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 717824-30-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dihydroorotate dehydrogenase (DHODH) | Target Info | Modulator | [2] |
| KEGG Pathway | Pyrimidine metabolism | |||
| Metabolic pathways | ||||
| Panther Pathway | De novo pyrimidine ribonucleotides biosythesis | |||
| Pathwhiz Pathway | Pyrimidine Metabolism | |||
| Reactome | Pyrimidine biosynthesis | |||
| WikiPathways | Metabolism of nucleotides | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2011 Pipeline of 4SC AG. | |||
| REF 2 | Company report (4SC) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.